98%
921
2 minutes
20
The lower all-cause mortality in women with Ductal carcinoma in situ (DCIS) compared with the general population has been hypothesized to be due to a "healthy-user effect," but this has not been studied in large cohorts. In a population-based, retrospective cohort study comprising 18,942 women with primary DCIS between 1999 and 2015 in the Netherlands, the cumulative incidence of breast cancer death (BCD) was estimated using death by other cause as a competing risk. The cause-specific mortality risk of women with DCIS was compared with that of the Dutch female population. Multivariable competing risk regression was used to quantify the effects of the method of detection and socio-economic status (SES). With 289 BCDs, the 10-year cumulative incidence of BCD was 1.3% (95% CI, 1.1-1.5). Compared to the Dutch female population, women with DCIS had a 2.1-times higher risk of BCD, but a 7% lower risk of all-cause mortality. Women with screen-detected DCIS had lower risks of BCD compared to women with non-screen-detected DCIS (subdistribution hazard ratio [sHR]:0.60, 95% CI 0.47-0.77), as did women with high SES versus low SES (sHR 0.54, 95% CI 0.30-0.97) in the first 4 years of follow-up, adjusted for age and year at diagnosis, and DCIS characteristics. In conclusion, overall mortality in women with DCIS is not higher compared to the Dutch female population, though death due to invasive breast cancer is increased. Within all women with DCIS, those with screen-detected DCIS or high SES had lower BCD and all-cause mortality, suggesting a healthy-user effect.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ijc.70112 | DOI Listing |
J Invest Surg
December 2025
Department of General Surgery, Hebei Province Hospital of Chinese Medicine, Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang, China.
Objective: This study aim to investigate the oncological safety of neoadjuvant therapy (NAT) followed by breast-conserving surgery (BCS) for invasive ductal carcinoma (IDC) patients with the presence of ductal carcinoma (DCIS) on pre-NAT biopsy.
Methods: The data of women with IDC who underwent radical surgery between January 2013 and December 2021 were retrospectively reviewed from two institutions. The study endpoints were 5-year disease-free survival (DFS) and local recurrence-fee survival (LRFS).
Health Commun
August 2025
Toronto General Hospital Research Institute, University Health Network.
Ductal carcinoma in situ (DCIS) is when abnormal cells are found in the milk ducts of the breast, but they have not spread outside the ducts. It is not an invasive cancer, but it can sometimes turn into cancer over time if not treated. Women with low or intermediate grade DCIS are counseled to undergo standards of care, which may include surgery, radiation, and/or endocrine therapy even though DCIS may not develop into breast cancer, prompting confusion and long-lasting anxiety.
View Article and Find Full Text PDFAnticancer Res
September 2025
HBOC-Center, Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin, Germany.
Background/aim: Precursor lesions, including B3 lesions of uncertain malignant potential, preinvasive lesions such as ductal carcinoma (DCIS), and invasive lesions identified in the breast tissue of carriers of pathogenic germline variants undergoing risk-reducing breast surgery, have received limited attention to date. This study aimed to assess the prevalence and histopathological features of these lesions, considering their genetic, demographic, and radiological characteristics.
Patients And Methods: We performed a retrospective monocentric cohort study analyzing 169 healthy women and patients after previous breast cancer who carried pathogenic germline variants in , and .
Clin Pract
August 2025
Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
: Breast cancer is the most prevalent malignancy among women globally. In Romania, it is the most frequent form of cancer affecting women, with approximately 12,000 new cases diagnosed annually, and the second most common cause of cancer-related mortality, second only to lung cancer. : This study looked at 79 breast cancer patients from Oltenia, concentrating on epidemiology, histology, diagnostic features, and treatments.
View Article and Find Full Text PDFInt J Cancer
August 2025
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
The lower all-cause mortality in women with Ductal carcinoma in situ (DCIS) compared with the general population has been hypothesized to be due to a "healthy-user effect," but this has not been studied in large cohorts. In a population-based, retrospective cohort study comprising 18,942 women with primary DCIS between 1999 and 2015 in the Netherlands, the cumulative incidence of breast cancer death (BCD) was estimated using death by other cause as a competing risk. The cause-specific mortality risk of women with DCIS was compared with that of the Dutch female population.
View Article and Find Full Text PDF